Recent trends and technological development in plasma as an emerging and promising technology for food biosystems.

The rising need for wholesome, fresh, safe and "minimally-processed" foods has led to pioneering research activities in the emerging non-thermal technology of food processing Cold plasma is such an innovative and promising technology that offers several potential applications in the food industry. It uses the highly reactive, energetic and charged gas molecules and species to decontaminate the food and package surfaces and preserve the foods without causing thermal damage to the nutritional and quality attributes of food. Cold plasma technology showed promising results about the inactivation of pathogens in the food industry without affecting the food quality.

Models of clinical care delivery for geriatric oncology in Canada and the United States: A survey of geriatric oncology care providers.

Background: Geriatric assessment (GA) can help improve patient care and outcomes. There are increasing numbers of centres in Canada and the United States (U.S.

Accrual of older adults to cancer clinical trials led by the Canadian cancer trials group - Is trial design a barrier?

Background: Older adults (OA), aged 65 years and over, are under-represented in studies. Strict exclusion criteria have been identified as a potential barrier to accrual of OA. This study aims to determine: 1) whether accrual of OA to trials led by the Canadian Cancer Trials Group (CCTG) has increased since 2003; 2) whether exclusion criteria have broadened over time; 3) whether exclusion criteria are associated with lower accrual of OA.

Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review.

Context: The number of older adults with cancer is expected to increase rapidly in the upcoming decades. Aging is heterogeneous and chronological age is often not reflective of biological age. A comprehensive geriatric assessment (CGA) is an in-depth assessment of multiple domains of health that results in better assessment of a patient's overall health and fitness and allows directed intervention to improve patient outcomes.

Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.

Purpose: A considerable challenge when comparing antiemetic trials for chemotherapy-induced nausea and vomiting (CINV) is the large number of outcome measures for nausea and vomiting. The objective of this study is to determine the optimal definition of CINV control from the patients' perspective.

Methods: Patients with early-stage breast cancer who had received anthracycline-cyclophosphamide-based chemotherapy were surveyed.